Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 24:7:29.
doi: 10.1186/1752-1947-7-29.

Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report

Claudio Ridolfi  1 , Giuseppe Pasini, Fabrizio Drudi, Eleonora Barzotti, Carlotta Santelmo, Antonio Polselli, Alberto Ravaioli
Affiliations

Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report

Claudio Ridolfi et al. J Med Case Rep. .

Abstract

Introduction: Uterine leiomyosarcoma is one of the most frequent uterine sarcomas. In the metastatic setting it is sensitive to doxorubicin, ifosfamide, gemcitabine, docetaxel and a few other drugs, but time to progression is generally short. For this reason prognosis is often poor and there are few reports in the literature of long responders.

Case presentation: We report a case of a 40-year-old Caucasian woman with metastatic uterine leiomyosarcoma who began treatment six years before the presentation of this case report and for the following six years underwent ten lines of chemotherapy, achieving excellent results and a good quality of life. Among the treatments administered we observed a long response to temolozomide, an unconventional drug for this kind of disease.

Conclusion: Although there are few chemotherapeutic options for the management of metastatic uterine leiomyosarcoma, a small number of patients have an unexpected long lasting response to treatment. For this reason further research is needed to identify new therapeutic agents and the predictive factors for the achievement of response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of temozolomide on pelvic metastasis. A: before the beginning of treatment. B: after 11 months of treatment.
Figure 2
Figure 2
Effect of temozolomide on one of the lung metastases. A: before the beginning of treatment. B: after 11 months of treatment.
See this image and copyright information in PMC

References

    1. Seddon BM, Davda R. Uterine sarcomas–Recent progress and future challenges. Eur J Radiol. 2011;78:30–40. doi: 10.1016/j.ejrad.2010.12.057. - DOI - PubMed
    1. Abd-Alla HM, El-Sebaie MM, Ali NM. Uterine sarcoma: analysis of treatment failure and survival. J Egypt Natl Canc Inst. 2000;12:245–251.
    1. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116:131–139. doi: 10.1016/j.ygyno.2009.09.023. - DOI - PubMed
    1. Kanjeekal S, Chambers A, Fung MF, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol. 2005;97:624–637. doi: 10.1016/j.ygyno.2005.01.041. - DOI - PubMed
    1. Hensley ML. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol. 2011;25:773–782. doi: 10.1016/j.bpobgyn.2011.06.003. - DOI - PubMed

LinkOut - more resources